Testosterone therapy is thought to increase bone density in older men with relatively low testosterone levels, but whether it prevents fractures is unclear. To address this question, researchers conducted a “subtrial” within TRAVERSE, the previously published randomized trial designed primarily to examine the cardiovascular (CV) safety of testosterone supplementation (NEJM JW Gen Med Jul 15 2023 and N Engl J Med 2023; 389:107).
In TRAVERSE, 5200 middle-aged and older men (mean, 63 years) with testosterone levels <300 ng/dL (median, 227 ng/dL) received testosterone gel or placebo. During median follow-up of about 3 years, the overall incidence of fractures (excluding sternum, fingers, toes, skull, and face) was significantly higher in the tes…
Reviewing Author
DisclosuresNothing to disclose
DisclosuresNothing to disclose